Search tips
Search criteria 


Logo of molmedLink to Publisher's site
Mol Med. 1997 May; 3(5): 327–338.
PMCID: PMC2230073

Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.


BACKGROUND: AIDS-associated Kaposi's sarcoma (AIDS-KS) represents one of the most common malignancies associated with human immunodeficiency virus infection. To target effective therapeutic agents to AIDS-KS, we have identified a new target in the form of interleukin-4 receptors (IL-4R). MATERIALS AND METHODS: The expression of IL-4R on AIDS-KS cells and their subunit structure was determined by radioligand receptor binding, cross-linking and Northern and RT-PCR analyses. The in vitro effect of IL-4 and recombinant fusion protein made up of circularly permuted IL-4 and a mutated form of Pseudomonas exotoxin, IL-4(38-37)-PE38KDEL, was examined by clonogenic and protein synthesis inhibition assays. RESULTS: Five AIDS-KS cell lines expressed high-affinity IL-4R with a Kd of 23.5-219 pM. IL-4 appeared to cross-link to one major protein corresponding to 140 kDa and a broad band corresponding to 60-70 kDa. Both cross-linked proteins were immunoprecipitated with an antibody to human IL-4R beta chain. AIDS-KS cells exhibited IL-4R beta-specific mRNA. IL-4 caused a modest inhibition (31-34%) of colony formation in two AIDS-KS cell lines tested. IL-4(38-37)-PE38KDEL was found to be highly effective in inhibiting the protein synthesis in all five AIDS-KS examined. The IC50 ranged from 32 to 1225 pM. The cytotoxic action of IL-4 toxin was blocked by an excess of IL-4, exhibiting the specificity of IL-4(38-37)-PE38KDEL. The cytotoxicity of IL-4 toxin observed by a clonogenic assay corroborated well with the IC50 obtained by protein synthesis inhibition assay. Normal human endothelial cells expressed a negligible number of IL-4R (< 50 sites/cell) and were less sensitive or not sensitive to IL-4(38-37)-PE38KDEL. CONCLUSION: The presence of a new plasma membrane protein in the form of IL-4R on AIDS-KS cells may be targeted by IL-4(38-37)-PE38KDEL for its potential implication in the treatment of AIDS-KS.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Friedman-Kien AE. Disseminated Kaposi's sarcoma syndrome in young homosexual men. J Am Acad Dermatol. 1981 Oct;5(4):468–471. [PubMed]
  • Gill PS. Pathogenesis of HIV-related malignancies. Curr Opin Oncol. 1991 Oct;3(5):867–871. [PubMed]
  • Werner S, Hofschneider PH, Roth WK. Cells derived from sporadic and AIDS-related Kaposi's sarcoma reveal identical cytochemical and molecular properties in vitro. Int J Cancer. 1989 Jun 15;43(6):1137–1144. [PubMed]
  • Corbeil J, Evans LA, Vasak E, Cooper DA, Penny R. Culture and properties of cells derived from Kaposi sarcoma. J Immunol. 1991 May 1;146(9):2972–2976. [PubMed]
  • Ensoli B, Barillari G, Gallo RC. Pathogenesis of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am. 1991 Apr;5(2):281–295. [PubMed]
  • Ganem D. AIDS. Viruses, cytokines and Kaposi's sarcoma. Curr Biol. 1995 May 1;5(5):469–471. [PubMed]
  • Miles SA. Pathogenesis of HIV-related Kaposi's sarcoma. Curr Opin Oncol. 1994 Sep;6(5):497–502. [PubMed]
  • Stürzl M, Roth WK, Brockmeyer NH, Zietz C, Speiser B, Hofschneider PH. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7046–7050. [PubMed]
  • Hermans P, Gori A, Lemone M, Franchioly P, Clumeck N. Possible role of granulocyte-macrophage colony stimulating factor (GM-CSF) on the rapid progression of AIDS-related Kaposi's sarcoma lesions in vivo. Br J Haematol. 1994 Jun;87(2):413–414. [PubMed]
  • Murakami-Mori K, Taga T, Kishimoto T, Nakamura S. AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies. J Clin Invest. 1995 Sep;96(3):1319–1327. [PMC free article] [PubMed]
  • Ensoli B, Nakamura S, Salahuddin SZ, Biberfeld P, Larsson L, Beaver B, Wong-Staal F, Gallo RC. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science. 1989 Jan 13;243(4888):223–226. [PubMed]
  • Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood. 1991 May 1;77(9):1859–1870. [PubMed]
  • Puri RK, Siegel JP. Interleukin-4 and cancer therapy. Cancer Invest. 1993;11(4):473–486. [PubMed]
  • O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993 Jan;91(1):83–87. [PMC free article] [PubMed]
  • Obiri NI, Siegel JP, Varricchio F, Puri RK. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol. 1994 Jan;95(1):148–155. [PubMed]
  • Taylor CW, Grogan TM, Salmon SE. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood. 1990 Mar 1;75(5):1114–1118. [PubMed]
  • Herrmann F, Andreeff M, Gruss HJ, Brach MA, Lübbert M, Mertelsmann R. Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood. 1991 Oct 15;78(8):2070–2074. [PubMed]
  • Toi M, Bicknell R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res. 1992 Jan 15;52(2):275–279. [PubMed]
  • Clerici M, Hakim FT, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, Shearer GM. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest. 1993 Mar;91(3):759–765. [PMC free article] [PubMed]
  • Park LS, Friend D, Sassenfeld HM, Urdal DL. Characterization of the human B cell stimulatory factor 1 receptor. J Exp Med. 1987 Aug 1;166(2):476–488. [PMC free article] [PubMed]
  • Ohara J. Interleukin-4: molecular structure and biochemical characteristics, biological function, and receptor expression. Year Immunol. 1989;5:126–159. [PubMed]
  • Murata T, Noguchi PD, Puri RK. Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells. J Biol Chem. 1995 Dec 22;270(51):30829–30836. [PubMed]
  • Kreitman RJ, Puri RK, Pastan I. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res. 1995 Aug 1;55(15):3357–3363. [PubMed]
  • Puri RK, Leland P, Obiri NI, Husain SR, Mule J, Pastan I, Kreitman RJ. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity. Cell Immunol. 1996 Jul 10;171(1):80–86. [PubMed]
  • Kreitman RJ, Puri RK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6889–6893. [PubMed]
  • Puri RK, Debinski W, Obiri N, Kreitman R, Pastan I. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin. Cell Immunol. 1994 Apr 1;154(1):369–379. [PubMed]
  • Puri RK, Leland P, Kreitman RJ, Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer. 1994 Aug 15;58(4):574–581. [PubMed]
  • Debinski W, Puri RK, Kreitman RJ, Pastan I. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. J Biol Chem. 1993 Jul 5;268(19):14065–14070. [PubMed]
  • Debinski W, Puri RK, Pastan I. Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin. Int J Cancer. 1994 Sep 1;58(5):744–748. [PubMed]
  • Masood R, Husain SR, Rahman A, Gill P. Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin. AIDS Res Hum Retroviruses. 1993 Aug;9(8):741–746. [PubMed]
  • Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem. 1995 Apr 14;270(15):8797–8804. [PubMed]
  • Reinecker HC, Podolsky DK. Human intestinal epithelial cells express functional cytokine receptors sharing the common gamma c chain of the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8353–8357. [PubMed]
  • Yoshida D, Piepmeier J, Weinstein M. Estramustine sensitizes human glioblastoma cells to irradiation. Cancer Res. 1994 Mar 15;54(6):1415–1417. [PubMed]
  • Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. [PubMed]
  • Zurawski SM, Vega F, Jr, Huyghe B, Zurawski G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J. 1993 Jul;12(7):2663–2670. [PubMed]
  • Obiri NI, Leland P, Murata T, Debinski W, Puri RK. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol. 1997 Jan 15;158(2):756–764. [PubMed]
  • Keegan AD, Beckmann MP, Park LS, Paul WE. The IL-4 receptor: biochemical characterization of IL-4-binding molecules in a T cell line expressing large numbers of receptors. J Immunol. 1991 Apr 1;146(7):2272–2279. [PubMed]
  • Galizzi JP, Zuber CE, Cabrillat H, Djossou O, Banchereau J. Internalization of human interleukin 4 and transient down-regulation of its receptor in the CD23-inducible Jijoye cells. J Biol Chem. 1989 Apr 25;264(12):6984–6989. [PubMed]
  • Galizzi JP, Castle B, Djossou O, Harada N, Cabrillat H, Yahia SA, Barrett R, Howard M, Banchereau J. Purification of a 130-kDa T cell glycoprotein that binds human interleukin 4 with high affinity. J Biol Chem. 1990 Jan 5;265(1):439–444. [PubMed]
  • Foxwell BM, Woerly G, Ryffel B. Identification of interleukin 4 receptor-associated proteins and expression of both high- and low-affinity binding on human lymphoid cells. Eur J Immunol. 1989 Sep;19(9):1637–1641. [PubMed]
  • Russell SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P, Friedmann MC, Miyajima A, Puri RK, Paul WE, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science. 1993 Dec 17;262(5141):1880–1883. [PubMed]
  • Vita N, Lefort S, Laurent P, Caput D, Ferrara P. Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types. J Biol Chem. 1995 Feb 24;270(8):3512–3517. [PubMed]
  • Freedman VH, Shin SI. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell. 1974 Dec;3(4):355–359. [PubMed]
  • Mosley B, Beckmann MP, March CJ, Idzerda RL, Gimpel SD, VandenBos T, Friend D, Alpert A, Anderson D, Jackson J, et al. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell. 1989 Oct 20;59(2):335–348. [PubMed]
  • Keegan AD, Nelms K, Wang LM, Pierce JH, Paul WE. Interleukin 4 receptor: signaling mechanisms. Immunol Today. 1994 Sep;15(9):423–432. [PubMed]
  • Harada N, Yang G, Miyajima A, Howard M. Identification of an essential region for growth signal transduction in the cytoplasmic domain of the human interleukin-4 receptor. J Biol Chem. 1992 Nov 15;267(32):22752–22758. [PubMed]
  • Obiri NI, Puri RK. Characterization of interleukin-4 receptors expressed on human renal cell carcinoma cells. Oncol Res. 1994;6(9):419–427. [PubMed]
  • Husain SR, Leland P, Aggarwal BB, Puri RK. Transcriptional up-regulation of interleukin 4 receptors by human immunodeficiency virus type 1 tat gene. AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1349–1359. [PubMed]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ